Medical Services International Inc. Receives Registration In Russia

EDMONTON, Alberta, Aug. 22 /PRNewswire-FirstCall/ -- Medical Services International Inc. (OTC: MSITF - News) is pleased to announce that it has received regulatory approval for its VScan HIV, Tuberculosis (TB) and Hepatitis C test kits in the Russian Federation. The Companies distributor in Russia "Intertest" A Pharmaceutical Company will immediately implement the marketing program for the approved VScan test kits. The Deputy of the General Director Ruzaev Evgeny Alexeevich who is responsible for the program feels that the demand for the VScan test kits will be substantial as a result of the independent testing completed and the regulatory approval. The VScan test kits continue to perform well wherever they are used. It is projected that sales will exceed 1,000,000 kits in the first year in Russia. The Company has obtained regulatory approval for the VScan HIV, TB and Hepatitis C test kits in both Russia and Ukraine. These two countries represent a large population that has a significant need for rapid test kits for HIV, TB and Hepatitis C.

The key to containing HIV and TB is early, fast, accurate testing. The VScan HIV test detects the IgM antigen that shows up in the blood within 2 to 11 days of HIV infection. The VScan TB test kit is the only test kit that measures only active TB and therefore does not give false positives. It is a fraction of the current cost of TB testing. TB is the number one killer of people with HIV/AIDS. It is projected by WHO that TB will kill over 8.0 million people this year. TB will kill more people this year than all other infectious diseases combined. Most TB is treatable with early detection.

About VScan

The VScan rapid test kit is a single use, disposable, accurate, cost effective, easy to use, test for the screening of HIV 1&2, Hepatitis B&C, Tuberculosis (TB), Dengue Fever, West Nile, Malaria, Syphilis and Prostate Cancer. The kits cannot be sold in Canada.

Medical Services International Inc. trades in the United States on the NQB Pinksheets under the symbol "MSITF". For further information, please contact Robert Talbot at (780) 430 6363 or at http://www.medicalservicesintl.com or http://www.minerva-biotech.com .

NOTE: Certain statements in this press release are "forward-looking statements" within the meaning of the Private Securities Act of 1995. Such statements involve known and unknown risks, uncertainties and other factors that may cause results to differ materially. Such risks, uncertainties and other factors include but are not limited to new economic conditions, risk in product development, market acceptance of new products and continuing product demand, level of competition and other factors described in Company reports and filings with regulatory bodies.

Source: Medical Services International Inc.